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ABSTRACT
Introduction MRI and MR spectroscopy (MRS) provide
early biomarkers of brain injury and treatment response
in neonates with hypoxic-ischaemic encephalopathy).
Still, there are challenges to incorporating neuroimaging
biomarkers into multisite randomised controlled trials. In
this paper, we provide the rationale for incorporating MRI
and MRS biomarkers into the multisite, phase III high-dose
erythropoietin for asphyxia and encephalopathy (HEAL)
Trial, the MRI/S protocol and describe the strategies used
for harmonisation across multiple MRI platforms.
Methods and analysis Neonates with moderate or
severe encephalopathy enrolled in the multisite HEAL
trial undergo MRI and MRS between 96 and 144 hours of
age using standardised neuroimaging protocols. MRI and
MRS data are processed centrally and used to determine
a brain injury score and quantitative measures of lactate
and n-acetylaspartate. Harmonisation is achieved through
standardisation—thereby reducing intrasite and intersite
variance, real-time quality assurance monitoring and
phantom scans.
Ethics and dissemination IRB approval was obtained at
each participating site and written consent obtained from
parents prior to participation in HEAL. Additional oversight
is provided by an National Institutes of Health-appointed
data safety monitoring board and medical monitor.
Trial registration number NCT02811263; Pre-result.

INTRODUCTION
Neonatal hypoxic-ischaemic encephalopathy
(HIE) is a major cause of death and neurodevelopmental disability, contributing to
almost a quarter of neonatal deaths worldwide.1–3 Therapeutic hypothermia (TH) is

Strengths and limitations of this study
►► This study will be the first to determine if high-dose

erythropoietin administered to infants with moderate
to severe neonatal hypoxic-ischaemic encephalopathy (HIE) reduces brain injury as measured by quantitative MRI and MR spectroscopy (MRS) biomarkers.
►► MRI and MRS data are collected prospectively, using
standardised MRI and MRS protocols, with quality
assurance and oversight provided by the high-dose
erythropoietin for asphyxia and encephalopathy
neuroimaging core.
►► Findings will clarify treatment effects of erythropoietin in neonates with HIE and will provide further
support of efficacy.
►► Limitations include the use of nine different MRI
platforms and clinical workflow, which poses challenges for harmonisation and for collecting quantitative data, including MRS files. Techniques for
mitigating these are discussed.

the first empirically supported therapy for
neuroprotection in neonates with HIE.2 3
Still, even with TH, 40%–50% of neonates die
or develop moderate to severe neurodevelopmental impairments.2 3 To improve outcomes,
efforts are focused on the development and
clinical translation of adjuvant neuroprotective therapies.
The high-
dose erythropoietin (Epo) for
asphyxia and encephalopathy (HEAL) trial
(NCT02811263) is a multicentre, randomised,
double-blind, placebo-controlled, phase
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III clinical trial designed to test the efficacy of Epo for
neuroprotection as an adjuvant to TH in neonates with
moderate to severe HIE.4 Preclinical studies have shown
that Epo induces multiple neuroprotective responses
that act synergistically to reduce brain injury, promote
repair and improve neurological outcomes after hypoxia-
ischaemia.5 Recent phase I/II clinical trials support the
safety of high-dose Epo and potential efficacy for neuroprotection in neonates with HIE.6–9 In the HEAL trial, 500
neonates with moderate or severe HIE undergoing TH
will be randomised to receive Epo (1000 U/kg) or placebo
on days 1, 2, 3, 4 and 7 of life. The primary endpoint is
the composite of death or neurodevelopmental impairment at 24 months of age. As a secondary aim, HEAL will
determine whether Epo decreases the severity of brain
injury by MRI and MR spectroscopy (MRS). In this paper,
we provide the rationale for incorporating MRI and MRS
biomarkers into the multisite, phase III HEAL trial, the
MRI/S protocol and describe the strategies used for
harmonisation across multiple MRI platforms.
Neuroimaging biomarkers of neonatal HIE
Neuroimaging
biomarkers
provide
information
regarding the nature and severity of the precipitating
insult, timing and prognosis. This is implied by the locus
and extent of injury and the signal characteristics on
T1-
weighted (T1w), T2-
weighted (T2w) and diffusion-
weighted imaging (DWI). Additionally, advanced techniques such as MRS provide biochemical information
regarding energy homoeostasis and injury progression,
while diffusion tensor imaging (DTI) provides information regarding microstructure and connectivity.
Patterns of injury
There are two hallmark patterns of injury associated
with neonatal HIE: a central pattern involving injury to
the deep grey nuclei (ventrolateral thalamus and posterior putamen) and perirolandic (paracentral) cortex,
with or without concomitant injury to the brainstem
and a peripheral pattern, involving injury to the white
matter and/or overlying cortex in a parasagittal distribution along the vascular borderzone (watershed territory). These patterns are similar to the patterns of injury
observed experimentally in primates following ‘near
total’ and ‘prolonged partial’ asphyxia, respectively.10–14
Other commonly observed findings in neonates with
HIE include punctate white matter lesions, focal lesions
(including strokes) and haemorrhages (intraventricular,
intraparenchymal and extra-
axial), as well as ‘normal’
MRIs (no apparent injury).15–20
Epidemiological neuroimaging data are limited, and
thus, the prevalence of various injury patterns in neonates
with mild, moderate or severe HIE, as classified by Sarnat
Stage, is not known. Multiple studies have investigated
whether the pattern of injury varies by maternal–fetal
factors, including sentinel events during delivery and
placental function; however, a consistent pattern has
yet to emerge. Several studies have shown that sentinel
2

events were associated with an increased risk of injury
to the thalamus/basal ganglia and/or cortex and white
matter21 22; however, the opposite has also been found.23
Likewise, placental abnormalities have been associated
with HIE24–26; however, there has been inconsistency with
regard to which placental findings are associated with
which pattern(s) of injury.27–30
Timing and evolution of HIE brain injury
HIE injury evolves over days, and serial imaging has
demonstrated this evolution is associated with varying
signal abnormalities on T1w and T2w MRI, DWI and
MRS. Acutely, injury appears as areas of restricted diffusion on Trace-
DWI and apparent diffusion coefficient
(ADC) maps. Quantitative measurements obtained in
neonates with HIE show that ADC values reach their
nadir 2–3 days after birth and rise thereafter, pseudonormalising at approximately 1 week after birth.31 32 These
curves are similar at 1.5 and 3T; however, measured ADC
values are inversely related to b-value, and higher b-values
(≥1000 s/mm2) are more sensitive for detecting acute
injury.33 34 TH augments the ADC curve producing lower
ADC values and may extend the time window for pseudonormalisation to as late as 8–10 days of age.35
Conventional MRI demonstrates parallel signal
changes. Acutely, oedema appears as areas of low signal
and high signal on T1w and T2w MRI, respectively. These
areas may show corresponding low ADC values indicating cytotoxic oedema (cell swelling). As injury evolves,
focal areas of T1 hyperintensity with correspondent T2
hypointensity begin to appear in the deep grey and/or
cerebral cortex, especially, in the ventrolateral thalamus,
posterolateral putamen and perirolandic cortex. Additionally, T1w and T2w imaging may show disruption of
the normal cortical ribbon, particularly in borderzone
(watershed) regions or in the vicinity of other focal injuries (eg, infarcts, contusions).
MRS demonstrates comparable changes in metabolite concentrations during the first and second week
after birth. Acutely, there is a rise in lactate, a marker
of anerobic metabolism; however, lactate peaks during
the first week, followed by a rise in lipids, which are only
detectable at short echo time.36 By contrast, n-
acetylaspartate (NAA), a marker of neuronal mitochondrial
metabolism, declines during the first few days and then
remains lower among HIE infants with brain injury.32 37–39
Other metabolites show transient changes following HIE
including phosphocreatine, myoinositol, glutamine and
choline.40–43
In conjunction with evolving signal abnormalities on
T1w, T2w, DWI and MRS, serial imaging has also shown
that the locus of injury may evolve during the first week.
This is especially common among infants with injury
to the deep grey matter who often demonstrate injury
localised to the ventrolateral thalamus +- dorsal brainstem on early scans (1–3 days of age), followed by more
widespread injury in the deep grey nuclei (particularly
posterolateral putamen) and perirolandic cortex on later
Wisnowski JL, et al. BMJ Open 2021;11:e043852. doi:10.1136/bmjopen-2020-043852
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scans (4+ days).15 32 44 Moreover, as injury evolves, areas of
Wallerian degeneration often appear on DWI, including
in the posterior limb of the internal capsule (PLIC), splenium and brainstem.15 32
MRI as a prognostic biomarker
MRI is widely employed clinically as a prognostic
biomarker, and several semiquantitative scoring systems
have been developed for use in clinical research.16 17 20 45–49
Most of these systems place greater weight on injury to
the grey matter (thalamus, basal ganglia and perirolandic
cortex) as these findings have been most consistently associated with adverse outcomes, including death and neurodevelopmental impairment.16 20 45–49 However, scoring
systems differ with regard to how they quantify severity,
with some inferring severity from the locus of the injury
alone16 39 45 while others infer severity from the locus and
extent of signal abnormality.20 48 Several yield information
regarding pattern of injury.16 44 45 None provide quantitative information regarding stage (ie, acute, subacute,
chronic) based on the evolving signal abnormalities on
MRI.
Several studies have assessed the validity of the
semiquantitative MRI scores in single centre45 48 and
multicentre studies.16 20 39 47 50 51 These studies have
demonstrated variable accuracy for predicting death or
neurodevelopmental impairment at follow-
up, ranging
from area under the curve (AUC) 0.7–0.99.20 37 48 51 Some
of this variability in predictive accuracy may be accounted
for by the timing of the MRI exams and the sequences
employed. Several studies have suggested that early scans
(<1 week) may provide better sensitivity while later scans
provide better specificity.51 52
Multiple studies have shown that MRS enhances the
predictive accuracy of MRI20 37 51 and several studies have
suggested that MRS may provide the highest predictive
accuracy of all MRI biomarkers.39 51 By contrast, quantitative ADC measurements have poor prognostic accuracy,51
likely due to pseudonormalisation, as discussed above.
Neuroimaging biomarkers in prior randomised controlled
trials for neuroprotection
MRI was included as a secondary outcome in three
previous phase III randomised controlled trials (RCTs)
for TH: the NICHD Neonatal Research Network (NRN)
Trial (2005),16 the Total Body Hypothermia for Neonatal
Encephalopathy (TOBY) Trial (2009)17 and the Infant
Cooling Evaluation (ICE) Trial (2011).47 All three trials
found that TH was associated with less injury on MRI.
Furthermore, the sensitivity and specificity of the MRI
biomarkers for predicting adverse outcome did not
differ between neonates who received TH and those who
received normothermia (NT), indicating that TH did not
alter the prognostic value of MRI in neonates with HIE.
However, the MRI results from the three cooling trials
varied in several important aspects. First, although TH
was associated with less brain injury on MRI in each trial,
the nature of the effect varied. In the TOBY Trial, TH
Wisnowski JL, et al. BMJ Open 2021;11:e043852. doi:10.1136/bmjopen-2020-043852

was associated with a reduction in signal abnormalities
in the basal ganglia/thalamus (BGT) (OR 0·36, 95% CI
0·15 to 0·84; p=0·02), white matter (0·30, 0·12 to 0·77;
p=0·01),and PLIC (0·38, 0·17 to 0·85; p=0·02).17 In
contrast, TH was not associated with a significant reduction in BGT injury in either the NICHD NRN or ICE trial,
but was associated with a significant reduction in injury to
the cortex and underlying white matter.16 47
The inconsistent MRI findings in the three cooling
trials are likely due, at least in part, to differences in study
design, including inclusion criteria, cooling technology
and neuroimaging methods. Moreover, only a subset
of patients in each trial had analyzable MRI data, and
both the proportion of patients in the MRI subanalyses,
which ranged from 40% to 65%, and relative proportion
assigned to each treatment group (TH vs NT) varied
across trials.16 17 47 Likewise, the MRI protocols differed
between trials (e.g., with or without DWI) as did the
timing of imaging, with mean age ranging from 647 to 15
days.16 Consistent with the variability in the neuroimaging
methods, the sensitivity and specificity of MRI biomarkers
as predictors of outcome varied substantially across trials,
with the highest sensitivity—but low specificity—in the
NICHD NRN trial, and the highest specificity—but low
sensitivity—in ICE.16 17 47 This variability limits any conclusions regarding differences in neuroimaging outcomes
across the three TH trials and points to the necessity of
standardisation and harmonisation.
Special considerations for MRS
Incorporating MRS into multisite trials poses additional
challenges beyond those encountered for conventional
MRI. Many hospitals do not routinely acquire MRS in
neonates with HIE as MRS requires specific software packages, which may not have been purchased. MRS acquisition is also more technically demanding due to its low
signal to noise ratio (SNR) compared with conventional
MRI.53 There are also challenges associated with detection
of lactate and other j-coupled metabolites that must be
addressed at acquisition and/or postprocessing in order
to avoid known pitfalls.54 Likewise, MRS analysis and
interpretation are more complex than conventional MRI
and require expert knowledge beyond core competence
in diagnostic radiology. Last, MRS has its own separate
billing code, and reimbursement is poor, often requiring
preauthorisation. Thus, although recommended by the
American College of Obstetrics and Gynecology task
force on Neonatal Encephalopathy and endorsed by the
American Academy of Pediatrics for assessment of brain
injury in neonatal HIE,55 MRS usage lags behind MRI.
MRS was not systematically incorporated into any prior
multicentre, phase III cooling trials for HIE, but it has
been incorporated into single-
centre32 41–43 56–58 and
multicentre observational studies39 59 as well as several
recent phase I/II RCTs.60 61 The sensitivity and specificity
of MRS for predicting outcome is not affected by TH,
making it suitable for use as a prognostic biomarker in
neonates undergoing TH for HIE.39 51 57 62–64 As with MRI,
3
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the reliability and diagnostic accuracy of MRS biomarkers
may be affected by the timing of exam, sequence parameters (short echo vs long echo), region sampled (BGT vs
white matter), postprocessing methods (ratios vs absolute
quantitation) and the precise metabolites chosen (eg,
lactate, NAA, creatine, choline).39 51 52
METHODS
In this section, we present the HEAL Neuroimaging
Protocol in accordance with the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
reporting guidelines.65
Study design
The HEAL trial is a multicentre, phase III, randomised,
double-
blind, placebo-
controlled trial involving 500
neonates, ≥36 weeks gestational age with moderate to
severe HIE who are undergoing TH. Treatment allocation
(Epo or placebo) is parallel (1:1), stratified by site and
HIE severity. Parents, participants and study personnel—
including the Neuroimaging Core—are blinded to the
treatment group. For further details regarding the HEAL
trial, please see online supplemental appendix 1 and also
Juul et al.4
MRI and MRS data are obtained at 4–5 days of age as
part of routine clinical care, using a standardised MRI
protocol. Neuroimaging data are then analysed centrally
by the HEAL Neuroimaging Core. Details regarding
acquisition, data transfer, data processing and analyses
are provided in the next section.
Patient and public involvement
This study was designed by the HEAL Study Group. There
is no parental advisory board. Results will be disseminated
to other physicians via academic medical conferences and
to the public at large via standard press releases.
Study locations
The HEAL trial is being carried out across a network of
17 study sites, using 9 MR platforms (table 1). Five of
the sites include two or more enrolling hospitals. Each
of the participating hospitals has a 3T MR system, with
the exception of one hospital, which is using a 1.5T MR
system and a dedicated neonatal head coil.
MRI and MRS sequences and sequence parameters
Prior to the start of HEAL enrolment, detailed MRI
protocols were developed for each MRI platform.
During the preparatory phase, we compared different
sequences and sequence parameters across platforms in
order to maximise consistency in image contrast, resolution and SNR across platforms using US Food and Drug
Administration-approved product sequences. The final
protocol is presented in table 2 (see also figures 1 and
2, eg, images). One limitation is that we were not able
to find an optimal solution for a 3 dimensions (3D) T2w
sequence. Therefore, we used a 2D sequence, with the
in-plane resolution matched to our 3D T1w sequence and
4

slice thickness at 2 mm (no gap) in alignment with our
DTI sequence.
The MRS protocol includes both short echo (TE 35)
and long-echo (TE 288) acquisitions. Furthermore, the
decision to use TE 288 over TE 144 mitigates a known
pitfall with lactate at 3T, namely the attenuation and even
absence of signal at TE 144 due to anomalous j-coupling,54
while the short echo (TE 35) acquisitions allow for quantitation of additional metabolites, including glutamate,
glutamine and lipids.
Timing of brain MRI and MRS
The target window for the HEAL MRI is day 4 or 5 after
birth (between 96 and 144 hours of age). This window
corresponds to a period of maximal sensitivity and specificity for MRI and MRS51 when abnormal DWI/ADC
signal is maximised51 57 and risk of pseudonormalisation
is minimised.31 44 Furthermore, this timing is compatible
with current clinical practice and provides information
to guide medical management including decisions about
redirection of care. For those infants who are not clinically
stable for MRI during this window, MRIs are obtained as
soon after the infant becomes clinically stable as possible.
Use of sedation
Because HEAL MRI scans are performed as part of routine
clinical care, the use of sedation is determined locally by
the attending physicians on a case-by-case basis. Given
concerns regarding possible neurotoxic effects of anaesthetic drugs,66 every effort has been made to facilitate
non-sedated imaging whenever possible. To determine
whether sedatives effect MRS metabolite concentrations,
all psychoactive medications administered within 4 hours
of the examination are recorded in the HEAL database.
Anonymisation and data transfer
Anonymisation and transfer of neuroimaging data is
facilitated by using a secure, Health Information Portability and Accountability Act (HIPAA)-compliant, cloud-
based service (Ambra Health, New York, New York, USA).
Because raw quantitative MRS data are not compatible
with clinical PACS systems, we developed specific protocols to transfer these data from the MR scanner in standard DICOM (Siemens), enhanced DICOM (Philips),
P-files (GE) other file formats (eg, SPAR/SDAT, RDA), as
needed. Furthermore, although the cloud-based service
provides anonymisation on upload to the HEAL Neuroimaging Core, uploading the raw MRS data requires
anonymisation prior to or during export from the MR
scanner as detailed in table 3.
Data processing: MRI
The primary HEAL neuroimaging outcome measures
is the total MRI injury score based on a previously validated MRI scoring system for HIE.48 This score indicates
the extent of signal abnormality (ie, 0=none, 1 ≤25%,
2=25%–50%, 3 ≥50%) for each of the deep grey nuclei,
PLIC, cerebral cortex, white matter and cerebellum, as
well as brainstem (scored on a 0–2 scale) separately for
Wisnowski JL, et al. BMJ Open 2021;11:e043852. doi:10.1136/bmjopen-2020-043852
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Table 1 Participating sites
Site

Hospital

MR manufacturer Model

On-site support
Software for HEAL

Seattle, WA*†‡
Columbus, OH

Seattle Children’s Hospital
Nationwide Children’s Hospital

Siemens
Siemens

Prisma
Skyra

E11
E11

Physicist
Physicist

Dallas, TX

Parkland Hospital

Siemens

Skyra

E11

MR Technologist

Indianapolis, IN

Riley Hospital for Children

Siemens

Skyra

E11

MR Technologist

Minneapolis-St. Paul,
MN‡

Children’s Hospital and Clinics of
Minnesota: Minneapolis

Siemens

Skyra

E11

MR Technologist

Minneapolis-St. Paul,
MN‡

Children’s Hospital and Clinics of
Minnesota: St. Paul

Siemens

Skyra

E11

MR Technologist

Philadelphia, PA

Children’s Hospital of Philadelphia

Siemens

Skyra

E11

Physicist

Pittsburgh, PA‡§

Children’s Hospital of Pittsburgh of
UPMC

Siemens

Skyra

E11

Physicist

Fort Worth, TX

Cook Children’s Medical Center

Siemens

Verio

B19

MR Technologist

San Antonio, TX‡

Children’s Hospital of San Antonio

Siemens

Verio

D13

MR Technologist

San Antonio, TX‡

Methodist Children’s Hospital

Siemens

Trio

B17

MR Technologist

St. Louis, MO§

Washington University Medical Center/ Siemens
St. Louis Children’s Hospital

Trio

B17

Physicist

Nashville, TN

Vanderbilt University Medical Center

Philips

Achieva

3.2

MR Technologist

Seattle, WA*,†‡

University of Washington Medical
Center

Philips

Achieva

5.3

Physicist

Cincinnati, OH

Cincinnati Children’s Hospital Medical
Center

Philips

Ingenia

5.3

Physicist

Los Angeles, CA§

Children’s Hospital Los Angeles

Philips

Ingenia

5.1.7

Physicist

San Francisco, CA*§

UCSF Benioff Children’s Hospital

GE

750

DV25

Physicist

Stanford, CA

Stanford University Medical Center

GE

750

DV26

Physicist

Washington, DC

Children’s National Medical Center

GE

750

DV26

Physicist

Salt Lake City, UT

Primary Children’s Medical Center/Univ. GE
of Utah
UPMC Magee Women’s Hospital
GE

Pittsburgh, PA‡

Architect DV27

MR Technologist

HDx¶

Physicist

DV24

*Clinical Coordinating Centre.
†Data Coordinating Centre.
‡Denotes sites with more than one enrolling hospital.
§Neuroimaging core.
¶1.5T MR system with dedicated neonatal head coil.
HEAL, high-dose erythropoietin for asphyxia and encephalopathy.

each sequence as shown in table 4. ‘Signal abnormality’
is defined qualitatively as either abnormally low or high
signal on T1w and T2w images or areas of restricted
diffusion on Trace-weighted or ADC images calculated
from the DTI sequence. We do not employ a quantitative threshold for ADC, consistent with the previously
validated scoring system.7 48 Areas with high ADC are not
scored as injury for the DTI images, which is designed
to measure acute injury; however, correspondent areas of
low and/or high signal on the T1w and/or T2w images
are scored.
For each ROI, injury is scored qualitatively for each
sequence on a 4-point scale based on the extent of signal
abnormality (0=none, 1 = <25%, 2=25%–50%, 3 ≥50%),
Wisnowski JL, et al. BMJ Open 2021;11:e043852. doi:10.1136/bmjopen-2020-043852

except for the brainstem which is scored on a 3-point
scale (0=none; 1=focal; 2=multifocal/widespread).
To compute the MRI injury score, each scan is reviewed
independently by two of three experienced readers
(AMM, JLW and RCM), who are blinded to the infant’s
clinical course, treatment assignment and MRS findings. After the primary review, each scan undergoes final
consensus review during which any discrepancies are
reviewed by all three reviewers and resolved by consensus.
The individual and consensus scores are then classified as
none (total=0), mild (1–11), moderate (12–32) or severe
(33–138), in accordance with the previously validated
MRI injury classification.48 Inter-rater reliability between
the three independent readers will be determined for
5
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Table 2 HEAL MRI sequences and sequence parameters
Siemens (Prisma, Skyra, Verio, Trio)

Philips (Achieva, Ingenia)

GE (MR750, MR750w, Architect)

MPRAGE

3D-TFE

IR-SPGR

T1w (3D)
 Sequence
 Resolution

1×1×1 mm

1×1×1 mm

1×1×1 mm

 Slice orientation

Sagittal

Sagittal

Sagittal

 TI

1100 ms

1000 ms

700 ms

 TE

3.05 ms

4.6 ms

3.16 ms

 TR

1550 ms

9.9 ms

8.15 ms

 Flip Angle

15

8

12

 Echo spacing*

9 ms

9.9 ms

8.36 ms

 Shot interval*

1550 ms

2000 ms

10.5 ms

 Bandwidth (pixel)

130 Hz

149 Hz

163 Hz

 Acceleration

GRAPPA (none)

SENSE (none)

SENSE (none)

 Reformats

Axial, Coronal

Axial, Coronal

Axial, Coronal

 TA

3:45

4:13

4:00

TSE or BLADE

TSE or MULTIVANE

FSE or PROPELLER

T2w (2D)
 Sequence
 Resolution

1×1×2 mm

1×1×2 mm

1×1×2 mm

 TE

≥120 ms (target=160 ms)

≥120 ms (target=160 ms)

≥120 ms (target=160 ms)

 TR

10 000 ms

10 000 ms

≥7000 ms

 ETL

15

15

13

 Acceleration

GRAPPA=2

SENSE=1.3

ASSET (≤2)

 TA

3:02

3:20

3:30

DTI
 Sequence

Ep_2D

DTI (‘High’)

DTI (30-dir)

 Resolution

2×2×2 mm

2×2×2 mm

2×2×2 mm

 TE

81 ms

88 ms

88 ms

 TR

10 200 ms

10 000 ms

7500 ms

 No of Dir.

30

32

30

 Max b-value

1000 s/mm2

1000 s/mm2

1000 s/mm2

 Acceleration

GRAPPA (2)

SENSE (2.2)

SENSE (2.2)

 TA

4:49

5:18

5:00

 Sequence

SVS-SE

PRESS

PROBE

 Resolution

17×17×17 (Thal/BG)

17×17×17 (Thal/BG)

17×17×17 (Thal/BG)

15×15×15 (par. WM)

15×15×15 (par. WM)

15×15×15 (par. WM)

35 ms (short-echo)

35 ms (short-echo)

35 ms (short-echo)

288 ms (long-echo)

288 ms (long-echo)

288 ms (long-echo)

MRS

 TE
 TR

2000 ms

2000 ms

2000 ms

 Bandwidth

2000 Hz

2000 Hz

2000 Hz

 NSA (metabolite)

128

128

128

 NSA (water)

6

16

16

 TA

4:28

4:48

4:48

*Note that although all three vendors use an ultrafast gradient echo sequence, the IR-SPGR (GE) differs from the others with regard to the timing of
the gradient echoes during acquisition, which prohibits direct comparisons between echo spacing and shot intervals across vendors.
3D, 3 dimensions; DTI, diffusion tensor imaging; ETL, echo train length; FSE, fast spin echo; GRAPPA, Generalized Autocalibrating Partially Parallel
Acquisition; HEAL, high-dose erythropoietin for asphyxia and encephalopathy; IR-SPGR, Inversion prepped spoiled gradient echo sequence; NSA,
Number of signal averages; SENSE, SENSitivity Encoding; TA, acquisition time; TE, echo time; TFE, Turbo Field Echo; TR, repetition time; TSE, turbo
spin echo; T2W, T2 weighted.
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Figure 1 Representative HEAL MRI at the level of the PLIC obtained at each of the participating HEAL sites. Harmonisation
centred on ensuring consistent sequences, sequence parameters and image resolution within and across participating
sites. ADC, apparent diffusion coefficient; DTI, diffusion tensor imaging; HEAL, High-Dose Erythropoietin for Asphyxia and
Encephalopathy.

both the total score and for the categorical classification
(none, mild, moderate, severe). For the total score, we
will use a general linear mixed effects model to estimate
the intraclass correlation coefficient (ICC).67 For the categorical classification, we will use kappa.68 Secondary MRI
measures include the MRI injury severity classification
discussed above as well as classification of injury pattern
and acuity. Injury pattern is classified as: (1) normal MRI
(defined as no evidence of injury); (2) central (injury to

the BGT±perirolandic cortex); (3) peripheral (injury to
the parasagittal cortex and/or WM, ie, ‘borderzone/watershed distribution); (4) global (injury to BGT+ total or near
total involvement of cortex±underlying WM); (5) punctate WM Lesions (discrete foci of injury typically 1–10 mm
in size localised to the periventricular WM or centrum
semiovale); (6) arterial ischaemic stroke (infarct localised
to the vascular territory of the middle, anterior or posterior cerebral arteries); (7) other focal lesions (includes

Figure 2 Representative MR spectra acquired at each of the participating HEAL sites on the same patients as in figure 1.
Note that two spectra were not available (n/a) from two patients above due to site-specific protocol constraints (top row) and
a technical problem (bottom row). HEAL, high-dose erythropoietin for asphyxia and encephalopathy; n/a, not available; TE,
echo time.
Wisnowski JL, et al. BMJ Open 2021;11:e043852. doi:10.1136/bmjopen-2020-043852
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Table 3 Procedures for exporting raw MRS data
Siemens

Philips

GE

Standard DICOM IMA
format

Enhanced DICOM
Classic DICOM

n/a

Non-DICOM
format

SPAR/SDAT

P-file (Pxxxxx.7)

Preferred format IMA
for export

Enhanced DICOM

P-file (Pxxxxx.7)

Anonymisation

During DICOM export

During DICOM export

Limitations

Requires direct export to
flash drive. If exporting to
CD/DVD, anonymisation
must be done manually

If scanner not configured to export
enhanced DICOM, it may be necessary
to export SPAR/SDAT, followed by
manual anonymisation of SPAR file

Prior to export by way of pfile_anon
(GE software)
If scanner not configured to allow
for telnet access, P-file must be
exported to DVD followed by manual
anonymisation of P-file

RDA

CD, compact disc; DICOM, Digital Imaging and Communications in Medicine, which is the international standard to transmit, store, retrieve,
print, process, and display medical imaging information; DVD, digital versitile disc.

venous infarcts, contusions, and unilateral lesions to the
BGT, cortex or white matter not classified elsewhere) and
(8) atypical/not otherwise specified (with additional text
field for describing the lesion). The scoring system allows
for multiple patterns to be coded, which will allow us to
determine the frequency of individual patterns as well as
the co-occurrence across patterns.
Acuity is defined by the co-occurrence of signal abnormalities across the MRI sequences. Of note, the HEAL MRI
examination occurs on day 4 or 5, prior to the expected
pseudonormalisation of the ADC signal, and final analyses
will be restricted to patients whose MRIs were completed
within the first week. Acute lesions are defined as lesions

that show correspondent diffusion restriction. Subacute
lesions are defined as lesions (signal abnormalities) on
T1w and/or T2w images without correspondent diffusion restriction (high or ‘normal’ ADC signal). Chronic
lesions are defined as lesions associated with volume loss
and tissue remodelling (eg, porencephalic cysts). As for
injury pattern, the scoring system permits coding multiple
levels of acuity (eg, acute + subacute injury).
Data processing: MRS
The primary MRS outcome measure is the ratio of lactate
to NAA. As secondary analyses, we will also determine
lactate and NAA concentrations (mmol/kg) as well as

Table 4 HEAL/Wash U MRI scoring system
T1

T2

Trace/ ADC

Caudate
Putamen/GP

BGT subscore

Total score

Thalamus
PLIC
Cortex

 

White Matter

 

Brainstem

 

Cerebellum
Injury pattern(s):

 
►► Normal MRI (no evidence of injury)
►► Central HIE Pattern (BGT±perirolandic cortex)
►► Peripheral Pattern (Parasagittal cortex and/or WM, that is, ‘watershed’)
►► Global Injury Pattern (BGT +total or near total involvement of cortex/WM)
►► Punctate WM Lesions (discrete foci of injury (typically ~1 to 10 mm in size

Classification
(independent of the
scores above)

localised to the periventricular WM or centrum semiovale)

►► Arterial Ischaemic Stroke
►► Other focal lesion (includes venous infarct±IPH; contusion; unilateral lesions

in BGT or other GM/WM not classified elsewhere)

►► Atypical pattern (please specify:
ADC, apparent diffusion coefficient; BGT, basal ganglia/thalamus; HEAL, high-dose erythropoietin for asphyxia and encephalopathy; HIE,
hypoxic-ischaemic encephalopathy.
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additional MRS metabolites. Raw MRS data (ie, quantitative files, see table 3) are processed centrally under
the direct supervision of SB and JLW using a modified
LCModel (V6.3–1 L, Stephen Provencher, Oakville,
Ontario, Canada) pipeline. This fully automated pipeline
applies zero-order and first-order corrections for phase,
estimates a baseline, corrects for ppm shift and eddy
currents, and determines metabolite concentrations, all
without need for user interaction. Data are fitted with
linear combinations of model spectra of known concentration from a standard basis set. For quantitation, the
unsuppressed water signal is used as a concentration
reference, with tissue water content estimated at a standardised value (ie, 86% or 47.8M) consistent with prior
published methods.43 69
Statistical analyses
The primary neuroimaging outcome measures are: (1)
the total injury score (derived from the HEAL/Wash U
MRI scoring system above) and (2) the ratio of lactate/
NAA determined for the left thalamus and parietal white
matter from the quantitative MRS data. For the MRI injury
score and the lactate/NAA ratio, we will use linear regression to compare Epo treated patients to controls while
adjusting for site and HIE severity since these are factors
used to stratify the randomisation. In the event that we
have missing data due to either early patient death or
other factors (eg, family declines MRI or infant is unable
to complete all of the sequences), we will estimate the
resultant sampling bias by comparing our final neuroimaging sample to the overall HEAL sample with regard to
patient demographics and primary outcome data.
Sample size
The sample size for the HEAL trial (n=500) is designed to
yield greater than 90% power to detect a relative reduction
in the rate of death or neurodevelopmental impairment
(primary outcome) of 33% in the Epo group as compared
placebo group.4 To calculate the sample size necessary for
the secondary neuroimaging analyses, we first calculated
the observed effect size for the MRI injury score for the
prior phase II trial.7 This study demonstrated a lower
brain injury score in Epo-treated infants as compared with
placebo (mean 5.26±9.9 vs 16.36±18.3, p<0.01, Cohen’s
d=0.75) and a lower rate of moderate/severe brain injury
(4% vs 44%, p<0.002). Using a conservative effect size for
HEAL (Cohen’s d=0.75/2) and controlling for multiple
comparisons, a total sample size of 356 will yield greater
than 90% power to detect a medium size effect (Cohen’s
d=0.375) on brain injury as measured by the MRI injury
score or lactate/NAA biomarker.
Neuroimaging harmonisation and quality assurance
The primary goal of harmonisation is to reduce measurement error by maximising the consistency of neuroimaging
data within and across sites. Minimising measurement
error maximises the standardised effect size and therefore statistical power.70 Intrasite and intersite variability in
Wisnowski JL, et al. BMJ Open 2021;11:e043852. doi:10.1136/bmjopen-2020-043852

MRI measurements can arise due to variability in: (1) MR
hardware (eg, field strength, gradient strength, sensitivity
of the head coils, hardware upgrades); (2) software (eg,
sequences, sequence parameters, software upgrades); (3)
patient workflow (eg, whether an infant is sedated or fed/
swaddled in an infant immobiliser; whether the infant is
properly positioned in the centre of the head coil) and
(4) the timing of the MRI (eg, before or after expected
pseudonormalisation of the diffusion signal). Additionally, noncompliance, a common challenge in multisite
studies, contributes further error. Although it is possible
to include ‘site’ as a covariate in statistical models, site
and scanner effects are often non-linear and non-uniform
across the brain as well as sequence-
specific, making
them challenging to manage retrospectively using statistical techniques. Accordingly, managing harmonisation
prospectively through study design and real-time monitoring are key to ensuring the reliability and reproducibility of the neuroimaging biomarkers.
Our harmonisation efforts for HEAL centre on two
areas: (1) a certification process to ensure that each site
was able to obtain high-quality data in accordance with
the HEAL protocol and (2) a robust quality assurance
process designed to monitor acquisition and mitigate
errors in a timely fashion throughout the trial. Prior to
the start of HEAL, we developed a standardised MRI/S
protocol and verified that it could be carried out across
platforms to generate resultant images that were comparable across platforms with regards to tissue contrast, resolution and SNR. Because the HEAL MRIs are acquired as
part of standard clinical care, as part of site initiation, we
had discussions with at least one neuroradiologist from
each site, as well as site PI, to ensure that the proposed
HEAL MRI/S protocol would meet the site’s requirements for a clinical MRI protocol and to mitigate any site-
specific challenges implementing the HEAL protocol.
Additionally, each site provided a test dataset, which were
used to verify sequence parameters, image homogeneity,
slice orientation and motion. MRS data were reviewed
for voxel position and raw data was processed to ensure
adequate line width and SNR. Furthermore, the test scans
certified the data transfer process and ensured that all
data, including raw MRS, could be captured from each
site and transferred to the HEAL Neuroimaging Core.
During the enrolment period, quality assurance is
maintained through a real-time process aimed at monitoring acquisition and mitigating any protocol deviations.
All brain MRI and MRS data are reviewed shortly after
being uploaded to the HEAL database. Any protocol deviations are recorded and each sequence (T1w, T2w and
DTI) is scored for motion on a four-point scale: none,
mild (unlikely to affect interpretation), moderate (may
affect interpretation), severe (obfuscates interpretation).
Likewise, MRS sequence parameters and voxel positions
are reviewed, and raw data are checked to ensure that
valid files are present for MRS processing. All protocol
deviations and severe motion or other artefacts are immediately discussed with the site.
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Phantom studies
The primary HEAL MRI and MRS endpoints, namely the
total MRI injury score and the ratio of lactate/NAA, were
designed to be robust across a wide range of scanner
platforms. However, to take full advantage of potential
secondary analyses, including quantitative MRS and DTI
biomarkers, we are carrying out additional phantom studies
during the HEAL trial. These phantoms studies are aimed at
further reducing unwanted site-related and scanner-related
variance from our quantitative MRS and DTI measures. For
MRS, we are using a commercially available phantom (GE
Healthcare), which contains physiological concentrations of
NAA, lactate, creatine, choline, glutamate and myoinositol.
For DTI, we are using the diffusion ice-
water phantom,
which leverages the known properties of water diffusion at
0°C.71 Both phantoms will be scanned on multiple days at the
HEAL neuroimaging core and twice within a single session
at participating HEAL sites using the HEAL MRS and DTI
protocols. We will use these data to compute the coefficient
of variation for each metabolite concentration and ADC
value across MR vendors, platforms and sites. These data will
not only provide an estimate of the degree of measurement
error that is attributable to scanner and site-specific effects,
but also help to inform whether we will need to deploy additional retrospective statistical approaches (eg, ComBat72) to
address unwanted site-related and scanner-related variance.
Unfortunately, we could not identify comparable phantoms with appropriate T1 and T2 values for an infant
brain and employing a ‘travelling infant’ as a phantom
was impractical. Thus, further harmonisation of the T1w
and T2w data will have to be carried out using retrospective statistical approaches.
DISCUSSION
The search for new neuroprotective therapies is ongoing,
not only for neonatal HIE, but also a range of disorders,
including stroke, traumatic brain injury and cardiac
arrest. As preclinical studies identify promising therapies, the research community needs reliable biomarkers
with which to move promising therapies from phase II to
phase III trials. This is critical, given the scarce resource of
appropriate patients and the cost of clinical trials. Neuroimaging biomarkers can help facilitate clinical translation
by providing early endpoints for evaluating treatment
efficacy. Furthermore, they can be used to elucidate treatment effects and the mechanisms by which improvements
in neurological outcomes are achieved.
At the same time, ensuring the reliability and reproducibility of neuroimaging data across a large-scale, multisite
RCT remains challenging. As a field, some of these challenges could be mitigated by adopting common protocols
for neuroimaging. This would not only aid in the reproducibility within and across trials, but also strengthen
research from bench to bedside by providing a means for
directly comparing the effects of therapies in preclinical
and clinical trials to those obtained in clinical practice.
Last, some of the technological challenges, such as MRS
10

data transfer and storage, would be eliminated if manufacturers were to use the standard DICOM format for
archiving MRS data, as was done for conventional MRI
more than three decades ago.
Summary
HEAL is the first phase III RCT for neuroprotection to
incorporate MRI, DTI and MRS biomarkers on a large scale.
We present standardised MRI and MRS protocols for HIE
that are feasible on any modern 3T platform and describe
our rigorous quality assurance procedures. Using phantom
studies, we will characterise the degree of unwanted site-
specific and scanner-specific effects remaining after harmonisation, which, in turn, will be used to estimate the need
for advanced statistical methods to reduce such nuisance
variance. Together, these methods will ensure rigour and
reliability of the neuroimaging biomarkers collected in
the HEAL trial and may help inform the design of future
neonatal neuroprotection trials.

ETHICS AND DISSEMINATION
The study protocol (currently: V.2.9, 18 March 2020), site-
specific informed consent forms, participant education
and recruitment materials and all study modifications
have been approved by the local Institutional Review
Board at each of the participating sites. Parents have
provided written permission for their child’s participation in the HEAL trial. Safety and progress reports are
provided to the NIH-appointed data safety monitoring
committee every 6 months.
Study findings will be disseminated through scientific
conferences, peer-reviewed journal publications, public
study website materials and invited lectures. Results from
this study will be reported according to SPIRIT guidelines65 and submitted for peer-
reviewed publication.
Individual participant data, including neuroimaging
data, will be made available through the National Institute of Neurological Disorders and Stroke (NINDS) Data
Archive: https://www.ninds.nih.gov/Current-Research/
Research-Funded-NINDS/Clinical-Research/Archived-
Clinical-Research-Datasets. The data will be deidentified
and a limited access data set will be available after March
2024 through a request form on that page. Data dictionaries, in addition to study protocol, the statistical analysis plan and the informed consent form will be included.
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